PSYBF PsyBio Therapeutics Corp

PsyBio Therapeutics Corp., a biotechnology company, develops formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders in the United States. It also engages in the research and development of naturally occurring tryptamines in varieties of hallucinogenic mushrooms, other tryptamines, phenethylamines, and combinations; and new molecular structures that do not occur in nature, which have therapeutics properties. The company is based in Coconut Creek, Florida.

Note: This is not a U.S. company, but they cross-list their shares on the U.S. over-the-counter market - see the related symbol CV:PSYB.

$0.16    OTCQB
As of 01/27/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  08/24/2021
Outstanding shares:  61,235,432
Average volume:  68,729
Market cap:   $9,687,445
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.93
PS ratio:   0.00
Return on equity:   -180.48%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy